SEATTLE, WA--(Marketwired - May 14, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Dr. Steven Quay, Chairman, CEO & President, will speak and participate on the Diagnostics panel at the Sachs Associates Cancer Bio Partnering Forum on Wednesday, May 22, 2013, at the Westin Copley Place in Boston, Massachusetts. Dr. Quay's corporate presentation will take place from 11:00 a.m. to 11:15 a.m. and the Diagnostics panel will take place from 11:55 a.m. to 12:25 p.m. Eastern Time.

Dr. Quay commented, "The Sachs Associates Cancer Bio Partnering Forum is a unique event that brings together a prestigious group of thought leaders and business development executives in the cancer biology space to discuss the latest advances in cancer diagnosis and treatments. I appreciate the opportunity to present our ForeCYTE Breast Health Test and other breast health products and laboratory services and to discussing our plans to develop an intraductal therapy for treatment of ductal carcinoma in situ (DCIS) in order to prevent breast cancer. I look forward to a highly productive meeting."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented diagnostic medical devices and patented laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA. The NRLBH provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating breast cancer cells and a tailored treatment plan for patients and their caregivers.

For additional information, please visit You can also view a video about the ForeCYTE test here:

Forward-Looking Statements

This press release is being issued for compliance with Regulation FD. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact Information:


Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel

Matthew D. Haines
MBS Value Partners